Article Data

  • Views 356
  • Dowloads 119

Original Research

Open Access

Pathological findings in early-stage endometrial cancer

  • S. Zehavi1
  • D. Schneider2
  • I. Bukovsky2
  • R. Halperin2,*,'

1Department of Pathology, Assaf Harofeh Medical Center

2 Zerifin, Affiliated with Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

3Department of Obstetrics & Gynecology, Assaf Harofeh Medical Center

4 Zerifin, Affiliated with Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

DOI: 10.12892/ejgo20030118 Vol.24,Issue 1,January 2003 pp.18-20

Published: 10 January 2003

*Corresponding Author(s): R. Halperin E-mail:

Abstract

Objective: The aim of this study was to assess the pathological characteristics of early-stage endometrial cancer, with regard to endometrioid versus serous papillary adenocarcinoma.

Methods: Sixty-six cases of early-stage endometrial carcinoma were classified into two groups: group I--36 cases of endometrioid endometrial cancer, staged IA-IB and graded G1-G2; group II--30 cases of Stage I serous papillary endometrial cancer. The pathological characteristics compared between the two groups included features such as tumor location in the uterine cavity, tumor focality, lymphovascular invasion, as well as the status of the uninvolved endometrium, adjacent to the tumor. Patient clinical characteristics were obtained from the medical records.

Results: Significantly more patients with endometrioid endometrial cancer were premenopausal (p < 0.0001), obese (p < 0.02), had hypertension (p < 0.00001) and familial cancer (p < 0.0001). On the other hand, significantly more patients with serous papillary cancer had another primary malignancy (p < 0.001). Considering the pathological characteristics, 75% of endometrioid as compared with 6.7% of serous papillary cancer cases were found in the upper uterine segment only (p < 0.0001). Multifocality was observed in 16.7% of endometrioid as compared with 100% of serous papillary cancer cases (p < 0.0001). Lymphovascular space invasion was absent in all cases of endometrioid cancer, while present in 90% of serous papillary cancer cases (p < 0.0001). Seventy-five percent of endometrioid and 100% of serous papillary cancer cases were associated with an atrophic endometrium.

Conclusion: The clinical and pathological features of early-stage endometrial cancer differ according to the histological type of the cancer. The majority of endometrioid cancers are probably associated with an atrophic or normally cycling endometrium, and not with endometrial hyperplasia.

Keywords

Early-stage endometrial cancer; Endometrioid endometrial cancer; Serous papillary endometrial cancer; Clinicopathological findings; Endometrial hyperplasia; Atrophic endometrium

Cite and Share

S. Zehavi,D. Schneider,I. Bukovsky,R. Halperin. Pathological findings in early-stage endometrial cancer. European Journal of Gynaecological Oncology. 2003. 24(1);18-20.

References

[1] Rose P. G.: "Endometrial carcinoma". N. Engl. J. Med., 1996, 335, 640.

[2] Burton J. L., Wells M.: "Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium" Histopathology, 1998, 33, 297.

[3] Kurman R. J., Zaino R. J., Norris N. J.: "Endometrial Carcinoma" In: Blaustein's Pathology of the Female Genital Tract. R. J. Kurman (ed), New York, Springer-Verlag, 1994, 439.

[4] Deligdisch L., Cohen C. J.: "Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia". Cancer, 1985, 56, 1452.

[5] Bokhman J. V.: "Two pathogenetic types of endometrial carcinoma". Gynecol. Oneal., 1983, 15, 10.

[6] Ayhan A., Yarali H., Ayhan A.: "Endometrial carcinoma: A pathologic evaluation of 142 cases with and without associated endometrial hyperplasia". J. Surg. Oneal., 1991, 46, 182

[7] Carcangiu M. L., Chambers J. T.: "Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival" Int. J. Gynecol. Pathol., 1995, 14, 30.

[8] Ohkawara S., Jobo T., Sato R., Kuramoto H.: "Comparison of endometrial carcinoma coexisting with and without endometrial hyperplasia". Eur. J. Gynecol. Oneal., 2000, 27, 573.

[9] Sivridis E., Fox H., Buckley C. H.: "Endometrial carcinoma: two or three entities?". Int. J. Gynecol. Cancer, 1998, 8, 183.

[10] Sivridis E., Giatromanolaki A.: "Prognostic aspects on endometrial hyperplasia and neoplasia". Virchows Arch., 2001, 439, 118.

[11] Westhoff C., Heller D., Drosinos S., Tancer L.: "Risk factors for hyperplasia-associated versus atrophy-associated endometrial carcinoma". Am. J. Obstet. Gynecol., 2000, 182, 506.

[12] Creasman W.: "Announcement. FIGO stages - 1988 revision". Gynecol. Oneal., 1989, 35, 125.

[13] Scully R. E., Kurman R. J., Silverberg S. G.: "Histological typrng of female genital tract tumors". 2"ct Ed. WHO International Histological Classification of Tumors. Berlin, Springer-Verlag, 1994.

[14] Kurman R. J., Zaino R. J., Norris H.J.: "Endometrial carcinoma". In: Blausteins's Pathology of the Female Genital Tract, R. J. Kurman (ed.). New York, Springer-Verlag, 1994, 439.

[15] Deligdisch L., Holinka C. F.: "Endometrial carcinoma: two diseases?". Cancer Detect. Prev., 1987, 10, 237.

[16] Beckner M. E., Mori T., Silverberg S. G.: "Endometrial carcinoma: on- tumor factors in prognosis". Int. J. Gynecol. Pathol., 1985, 4, 131

[17] Phelan C., Montag A. G., Rotrnensch J., Waggoner S. E., Yamada S. D., Mundt A. J.: "Outcome and management of pathological stage I endometrial carcinoma patients with involvement of the lower uterine segment". Gynecol. Oneal., 2001, 83, 513.

[18] Ambros R. A., Sherman M. E., Zahn C. M., Bitterman P., Kurman R. J.: "Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumours displaying serous differentiation". Hum. Pathol., 1995, 26, 1260.

[19] Kaku T., Tsukamoto N., Hachisuga T., Tsuruchi N., Sakai K., Hirakawa T. et al.: "Endometrial carcinoma associated with hyperplasia". Gynecol. Oneal., 1996, 60, 22.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top